# US 2016/0235830 A1 · Chimeric ospa genes, proteins and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235830 A1
- Document ID: US20160235830A1
- Status: Published application
- Kind: A1
- Application number: 15/049,438
- Filed: 2016-02-22
- Published: 2016-08-18
- Earliest claimed: 2010-05-14
- Assignees: Baxalta Incorporated; The Research Foundation of State University of New York; Brookhaven Science Associates, LLC
- Applicants: Baxalta Incorporated; Baxalta GmbH; Research Foundation of the State University of New York; Brookhaven Science Associates, LLC
- Inventors: Brian A. Crowe; Ian Livey; Maria O'Rourke; Michael Schwendinger; John J. Dunn; Benjamin J. Luft
- Web page: https://patentgrep.com/patent/US20160235830A1

## CPC

- A61K 39/0225: {Spirochetes, e.g. Treponema, Leptospira, Borrelia}
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/14: for RNA viruses
- A61P 33/00: Antiparasitic agents
- A61P 33/14: Ectoparasiticides, e.g. scabicides
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/20: from Spirochaetales (O), e.g. Treponema, Leptospira
- A61K 2039/575: {humoral response}
- A61K 2039/6018: {Lipids, e.g. in lipopeptides}
- A61K 2039/70: {Multivalent vaccine}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention relates to the development of chimeric OspA molecules for use in a new Lyme vaccine. More specifically, the chimeric OspA molecules comprise the proximal portion from one OspA serotype, together with the distal portion from another OspA serotype, while retaining antigenic properties of both of the parent polypeptides. The chimeric OspA molecules are delivered alone or in combination to provide protection against a variety of Borrelia genospecies. The invention also provides methods for administering the chimeric OspA molecules to a subject in the prevention and treatment of Lyme disease or borreliosis.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

An isolated polypeptide selected from the group consisting of:
a) an isolated polypeptide comprising an amino acid sequence having at least 90 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10;
b) an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10; and
c) an isolated polypeptide consisting of the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.

### Claim at position 3

20-24. (canceled)

### Claim 25 (depends on 19)

A composition comprising the polypeptide of claim 19 and a pharmaceutically acceptable carrier.

### Claim at position 5

26-27. (canceled)

### Claim 28 (depends on 25)

An immunogenic composition comprising the composition of claim 25 and an adjuvant.

### Claim at position 7

29-34. (canceled)

### Claim 35 (depends on 28)

A vaccine composition comprising the immunogenic composition of claim 28 and a pharmaceutically acceptable carrier.

### Claim at position 9

36-40. (canceled)

### Claim 41 (depends on 28)

A method for inducing an immunological response in a subject, the method comprising the step of administering the composition of claim 28 to the subject in an amount effective to induce an immunological response.

### Claim 42

(canceled)

### Claim 43 (depends on 35)

A method for preventing or treating a Borrelia infection or Lyme disease in a subject, the method comprising the step of administering the vaccine composition of claim 35 to the subject in an amount effective to prevent or treat the Borrelia infection or Lyme disease.

### Claim at position 13

44-51. (canceled)

### Claim 52 (depends on 19)

The isolated polypeptide of claim 19 comprising an amino acid sequence having at least 91 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.

### Claim 53 (depends on 19)

The isolated polypeptide of claim 19 comprising an amino acid sequence having at least 92 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.

### Claim 54 (depends on 19)

The isolated polypeptide of claim 19 comprising an amino acid sequence having at least 93 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.

### Claim 55 (depends on 19)

The isolated polypeptide of claim 19 comprising an amino acid sequence having at least 94 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.

### Claim 56 (depends on 19)

The isolated polypeptide of claim 19 comprising an amino acid sequence having at least 95 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.

### Claim 57 (depends on 19)

The isolated polypeptide of claim 19 comprising an amino acid sequence having at least 96 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.

### Claim 58 (depends on 19)

The isolated polypeptide of claim 19 comprising an amino acid sequence having at least 97 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.

### Claim 59 (depends on 19)

The isolated polypeptide of claim 19 comprising an amino acid sequence having at least 98 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.

### Claim 60 (depends on 19)

The isolated polypeptide of claim 19 comprising an amino acid sequence having at least 99 percent sequence identity to the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.

### Claim 61 (depends on 19)

The isolated polypeptide of claim 19 consisting of the amino acid sequence set forth in SEQ ID NO: 4 or SEQ ID NO: 10.

### Claim 62 (depends on 61)

A composition comprising the isolated polypeptide of claim 61 and a pharmaceutically acceptable carrier.

### Claim 63 (depends on 62)

An immunogenic composition comprising the composition of claim 62 and an adjuvant.
